4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Holders of 5% or more of FDMT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of 4D Molecular Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%5.85M shares | 0.00 ppfrom 9.99% | Feb 14, 20253 filings | Feb 17, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%5.71M shares | 0.00 ppfrom 9.90% | Feb 14, 20252 filings | Feb 17, 2026 | SEC |
| Janus Henderson Group PLC | 13G | 8.10%4.64M shares | +3.20 ppfrom 4.90% | Feb 14, 20252 filings | Feb 17, 2026 | SEC |
| Goldman Sachs Group Inc | 13G/A | 7.50%4.29M shares | −2.10 ppfrom 9.60% | Feb 10, 20252 filings | Feb 9, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.60%3.06M shares | −1.20 ppfrom 7.80% | Apr 17, 20252 filings | Oct 17, 2025 | SEC |
| Novo Holdings A/S | 13G/A | 6.40%3.65M shares | −0.40 ppfrom 6.80% | Oct 20, 20252 filings | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
17 Schedule 13D and 13G filings on 4D Molecular Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20269:02 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20266:55 PM ET | Novo Holdings A/S | 13G/A | 6.40%3.65M shares | −0.40 ppfrom 6.80% | Dec 31, 2025 | SEC |
| Feb 17, 20264:15 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%5.71M shares | 0.00 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 17, 20264:12 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%5.85M shares | 0.00 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 17, 202612:42 PM ET | Janus Henderson Group PLC | 13G | 8.10%4.64M shares | +3.20 ppfrom 4.90% | Dec 31, 2025 | SEC |
| Feb 9, 20264:05 PM ET | Goldman Sachs Group Incand 1 other | 13G/A | 7.50%4.29M shares | −2.10 ppfrom 9.60% | Dec 31, 2025 | SEC |
| Oct 20, 20255:12 PM ET | Novo Holdings A/S | 13G | 6.80%3.17M shares | New | Oct 13, 2025 | SEC |
| Oct 17, 20256:13 PM ET | BlackRock, Inc. | 13G/A | 6.60%3.06M shares | −1.20 ppfrom 7.80% | Sep 30, 2025 | SEC |
| May 15, 20255:44 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 1.50%677.6K shares | −4.90 ppfrom 6.40%Below 5% | Mar 31, 2025 | SEC |
| May 15, 20254:29 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%4.63M shares | 0.00 ppfrom 9.99% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.80%3.62M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20256:30 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%4.56M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20256:09 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 6.40%2.95M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20254:20 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%4.83M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 202511:34 AM ET | Janus Henderson Group PLC | 13G/A | 4.90%2.25M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20258:40 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 1.32%609.9K shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 10, 20255:28 PM ET | Goldman Sachs Group Incand 1 other | 13G/A | 9.60%4.42M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell 4D Molecular Therapeutics, Inc. shares.
No Form 144 notices for 4D Molecular Therapeutics, Inc. are on file.